$TEVA - Very important stripe 11.2-10.7Next support - 9.75
Good-luck to holders, Not for a suggestion.
TEVA/N trade ideas
TEVA doughAnalysis done on 25/05/2020
Fundamental
→ 20 & 40 SMA sloping up
→ 20MA > 40MA
Awaiting buy trigger
→ CCI <-100
→ Low of daily bar touches 20MA or goes below 20MA
→ Close above 40MA
Pull trigger
→ Buy 1 bid above previous day high
→ Sell 5 bars later exclusive of initial bar
Stop Loss
→ 50% below price bought
TEVA, Upside potential, Good RR
Good risk reward on the technical side.
Looking at the $16 price target. Potential to go higher on break.
TEVA short-term shortMore optimistic over 1/1 Gann fan, bullish over 2/1 and back into channel and above resistance. Overall nice medium term reversal pattern.
$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov
Weekly chart is flashing buy signals with the 50SMA Crossing back under the price.
Unknowns: COVID-19 impact on TEVA earnings
Decision - Wait until after earnings to get in, still to many unknowns.
The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit.
Earnings (loss) per share attributable to ordinary shareholders:
Basic ($)
2020 - Lower?
2019 - (0.91) even lower?
2018 - (2.35) Lower loss
2017 - (16.26) Huge loss
2016 - 0.07 Smaller profit
2015 - 1.84 Profit
Diluted ($)
2019 - (0.91)
2018 - (2.35)
2017 - (16.26)
2016 - 0.07
2015 -1.82
www.sec.gov
tevai would not long unless longterm trend line breaks with buy pressure. if it breaks maybe it can go to new highs
TEVA - 4/20/2020TEVA - Tenkan sen is about to cross death of Kijun sen is a bad sign. In addition, both lines are about the get into cloud means increased volatility ahead, struggling inside the cloud. TEVA is a sell here.
$TEVA - Respect the price 10$, its the support now.Above MA50 and MA200 (with a hope it will stay above it).
Next target is 12$.
Below 10$, I save the respect to 8.95 with price closing.
Not for a suggestion.
TEVA Pharma attempting to break long term trend
Moving average currently holding as support
Above $10.50 a possible long
$12.00 a short term target below long term trendline.
teva cup patternTeva seems to have the cup with handle pattern.
The next resistance line is at 13.50 ish, so until then it looks like teva will rise up and then bounce back a little bit to 11/12. It may also be possible that Teva can reach 20 in September
$TEVA Catches Fresh Momo as Malaria Drugs Get the NodTEVA shares are popping to start off the week as the company gets into the middle of the chloroquine emphasis to battle the COVID-19 outbreak. The longer-term picture is defined by the potential for fresh momentum after successfully holding key support.
TEVA building a Cause?This is still a while out (I think) but its been added to the watchlist for sure.
Teva Pharmaceutical $TEVAIt couldn't' break first fibonacci level and rsi 50. It is going down for double bottom?
TEVA Pharmaceuticals Potentially forming a Falling Wedge BottomIn my experience trendly / volatile stocks have a tendency to have significant long term reversals from wedges and general downtrendline breaks. Extremely interested to see where this goes, if it does end up breaking out bullishly. Company could begin a new bull run, or simply reach target and mean revert.
Juicy After Hours MoveI've been thinking the bottom was near considering Teva is a pharmaceutical company. With the news of Israel shutting down (with exception of grocery/pharmacy) due to the Corona Virus, we may have the catalyst we needed for a reversal. Business will not be effected and opiate settlement will be hard to continue to fight with governments needing all pharma on deck. BUY BUY BUY.
Teva Pharmaceutical Industries Ltd covic-19 Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need.
"We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost," said Brendan O’Grady, Teva Executive Vice President, North America Commercial. "Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately."
Additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from our ingredient supplier. Teva will ship 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month.
Hydroxychloroquine sulfate tablets manufactured by Teva are approved by U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is currently under investigation for efficacy against the coronavirus and has been requested by US government officials to be made available for use immediately. The Company is also reviewing supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients.
Teva is also actively looking across its expansive range of products to determine if the company can help to provide any other products that may be relevant in addressing acute and substantial need during the COVID-19 crisis.
